The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: Experience from one center

Journal of Endocrinological Investigation

Volumn 33, Issue 11, 2010, Pages 794-799

  Nikolaou, A ^a   Thomas, Dimitrios ^a   Kampanellou, C ^b   Alexandraki, K ^a   Andersson, L G ^b   Sundin, A ^b   Kaltsas, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C 5 HTP PET CT; Neuroendocrine tumors

Indexed keywords

5 HYDROXYTRYPTOPHAN C 11; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 5 HYDROXYTRYPTOPHAN; CARBON; DIAGNOSTIC AGENT;

ADRENALECTOMY; ADULT; ARTICLE; BRONCHUS CARCINOID; CANCER STAGING; CARCINOID; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECTOPIC CORTICOTROPIN PRODUCTION; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE TUMOR; THYROID MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

5-HYDROXYTRYPTOPHAN; ACTH SYNDROME, ECTOPIC; ADULT; CARBON RADIOISOTOPES; CARCINOID TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78049347762     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6936     Document Type: Article

References (27)

1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458-511. (Pubitemid 38780668)
2. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004, 151: 15-27. (Pubitemid 39117361)
3. Bombardiert E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004, 48: 150-63.
4. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000, 62: 33-8. (Pubitemid 30665937)
5. Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995, 25: 251-61.
6. Eriksson B, Bergström M, Sundin A, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002, 970: 159-69. (Pubitemid 35286093)
7. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of the positron emission tomography. Endocr Rev 2004, 25: 569-80.
8. Neels OC, Koopmans KP, Jager PL, et al. Manipulation of [11C)-5hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res 2008, 68: 7183-9.
9. Sundin A, Errikson B, Bergström M, et al. Demonstration of [11C) 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 2000, 27: 33-41. (Pubitemid 30099612)
10. Orlefors H, Sundin A, Alhström H, et al. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. J Clin Oncol 1998, 16: 2534-41. (Pubitemid 28309052)
11. Bjurling P, Watanabe Y, Tokushige M, Oda T, Långström B. Synthese of β-11C-labelled L-tryptophan and 5-hydroxy-L-tryptophan using a multienzymatic reaction route. J Chem Soc Perkin Transact 1989, 1: 1331-4.
12. Scarsbrook AS, Ganeshan A, Statham J, et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 2007, 27: 455-76.
13. Rockal AG, Reznek RH. Imaging of neuroendocrine tumors (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007, 21: 43-68.
14. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001, 86: 895-902. (Pubitemid 32207512)
15. Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med 2000, 30: 195-208. (Pubitemid 30469916)
16. Kälkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995, 55: 5801-4.
17. Modlin IM, Cornelius E, Lawton GP. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995, 130: 367-73.
18. de Herder WW, van der Lelly AJ, Lamberts SW. Somatostatin analog treatment of neuroendocrine tumours. Postgrad Med J 1996, 72: 403-8. (Pubitemid 26237379)
19. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)and (123I-Tyr3)-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20: 716-31. (Pubitemid 23284773)
20. de Herder WW, Kwekkeboom DJ, Valkema R, Lamberts SW. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005, 28: 132-6.
21. Sundin A, Eriksson B, Bergström M, Långström B, Oberg K, Orlefors H. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004, 1014: 246-57. (Pubitemid 38594812)
22. Orlefors H, Sundin A, Garske U, et al. Whole body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005, 90: 3392-400. (Pubitemid 41014303)
23. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-Dihydroxy-Phenyl-Alanine and 11C-5-hydroxy-tryptophan Positron Emission Tomography. J Clin Oncol 2008, 26: 1489-96.
24. Haug A, Auernhammer CJ, Wangler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009, 36: 765-70.
25. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumour imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumours with poor prognosis and aggressive behaviour. World J Surg 1998, 22: 588-92. (Pubitemid 28215437)
26. Eriksson B, Orlefors H, Oberg K, et al. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005, 19: 311-24. (Pubitemid 40347819)
27. Gourgiotis L, Sarlis NJ, Reynolds JC, Vanwaes C, Merino MJ, Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-(F-18)-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003, 88: 637-41. (Pubitemid 36207803)